O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation. 2011

Simone Kreth, and Niklas Thon, and Sabina Eigenbrod, and Juergen Lutz, and Carola Ledderose, and Rupert Egensperger, and Joerg C Tonn, and Hans A Kretzschmar, and Ludwig C Hinske, and Friedrich W Kreth
Department of Anaesthesiology, Ludwig Maximilians University, Munich, Germany. fkreth@med.uni-muenchen.de

BACKGROUND We analyzed prospectively whether MGMT (O(6)-methylguanine-DNA methyltransferase) mRNA expression gains prognostic/predictive impact independent of MGMT promoter methylation in malignant glioma patients undergoing radiotherapy with concomitant and adjuvant temozolomide or temozolomide alone. As DNA-methyltransferases (DNMTs) are the enzymes responsible for setting up and maintaining DNA methylation patterns in eukaryotic cells, we analyzed further, whether MGMT promoter methylation is associated with upregulation of DNMT expression. RESULTS ADULT PATIENTS WITH A HISTOLOGICALLY PROVEN MALIGNANT ASTROCYTOMA (GLIOBLASTOMA: N = 53, anaplastic astrocytoma: N = 10) were included. MGMT promoter methylation was determined by methylation-specific PCR (MSP) and sequencing analysis. Expression of MGMT and DNMTs mRNA were analysed by real-time qPCR. Prognostic factors were obtained from proportional hazards models. Correlation between MGMT mRNA expression and MGMT methylation status was validated using data from the Cancer Genome Atlas (TCGA) database (N = 229 glioblastomas). Low MGMT mRNA expression was strongly predictive for prolonged time to progression, treatment response, and length of survival in univariate and multivariate models (p<0.0001); the degree of MGMT mRNA expression was highly correlated with the MGMT promoter methylation status (p<0.0001); however, discordant findings were seen in 12 glioblastoma patients: Patients with methylated tumors with high MGMT mRNA expression (N = 6) did significantly worse than those with low transcriptional activity (p<0.01). Conversely, unmethylated tumors with low MGMT mRNA expression (N = 6) did better than their counterparts. A nearly identical frequency of concordant and discordant findings was obtained by analyzing the TCGA database (p<0.0001). Expression of DNMT1 and DNMT3b was strongly upregulated in tumor tissue, but not correlated with MGMT promoter methylation and MGMT mRNA expression. CONCLUSIONS MGMT mRNA expression plays a direct role for mediating tumor sensitivity to alkylating agents. Discordant findings indicate methylation-independent pathways of MGMT expression regulation. DNMT1 and DNMT3b are likely to be involved in CGI methylation. However, their exact role yet has to be defined.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011401 Promoter Regions, Genetic DNA sequences which are recognized (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the Pribnow box in bacteria and the TATA BOX in eukaryotes. rRNA Promoter,Early Promoters, Genetic,Late Promoters, Genetic,Middle Promoters, Genetic,Promoter Regions,Promoter, Genetic,Promotor Regions,Promotor, Genetic,Pseudopromoter, Genetic,Early Promoter, Genetic,Genetic Late Promoter,Genetic Middle Promoters,Genetic Promoter,Genetic Promoter Region,Genetic Promoter Regions,Genetic Promoters,Genetic Promotor,Genetic Promotors,Genetic Pseudopromoter,Genetic Pseudopromoters,Late Promoter, Genetic,Middle Promoter, Genetic,Promoter Region,Promoter Region, Genetic,Promoter, Genetic Early,Promoter, rRNA,Promoters, Genetic,Promoters, Genetic Middle,Promoters, rRNA,Promotor Region,Promotors, Genetic,Pseudopromoters, Genetic,Region, Genetic Promoter,Region, Promoter,Region, Promotor,Regions, Genetic Promoter,Regions, Promoter,Regions, Promotor,rRNA Promoters
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D003606 Dacarbazine An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564) DTIC,5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide,Biocarbazine,DIC,DTIC-Dome,Decarbazine,Deticene,Dimethyl Imidazole Carboxamide,Dimethyl Triazeno Imidazole Carboxamide,ICDT,NSC-45388,Carboxamide, Dimethyl Imidazole,DTIC Dome,DTICDome,Imidazole Carboxamide, Dimethyl,NSC 45388,NSC45388
D005260 Female Females
D005910 Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21) Glial Cell Tumors,Malignant Glioma,Mixed Glioma,Glial Cell Tumor,Glioma, Malignant,Glioma, Mixed,Gliomas,Gliomas, Malignant,Gliomas, Mixed,Malignant Gliomas,Mixed Gliomas,Tumor, Glial Cell,Tumors, Glial Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077204 Temozolomide A dacarbazine derivative that is used as an alkylating antineoplastic agent for the treatment of MALIGNANT GLIOMA and MALIGNANT MELANOMA. 8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one,CCRG 81045,CCRG-81045,M&B 39831,M&B-39831,Methazolastone,NSC 362856,NSC-362856,TMZ-Bioshuttle,TMZA-HE,Temodal,Temodar,Temozolomide Hexyl Ester,CCRG81045,M&B39831,NSC362856,TMZ Bioshuttle

Related Publications

Simone Kreth, and Niklas Thon, and Sabina Eigenbrod, and Juergen Lutz, and Carola Ledderose, and Rupert Egensperger, and Joerg C Tonn, and Hans A Kretzschmar, and Ludwig C Hinske, and Friedrich W Kreth
March 2008, Journal of neuro-oncology,
Simone Kreth, and Niklas Thon, and Sabina Eigenbrod, and Juergen Lutz, and Carola Ledderose, and Rupert Egensperger, and Joerg C Tonn, and Hans A Kretzschmar, and Ludwig C Hinske, and Friedrich W Kreth
July 2013, DNA and cell biology,
Simone Kreth, and Niklas Thon, and Sabina Eigenbrod, and Juergen Lutz, and Carola Ledderose, and Rupert Egensperger, and Joerg C Tonn, and Hans A Kretzschmar, and Ludwig C Hinske, and Friedrich W Kreth
June 1994, The Journal of biological chemistry,
Simone Kreth, and Niklas Thon, and Sabina Eigenbrod, and Juergen Lutz, and Carola Ledderose, and Rupert Egensperger, and Joerg C Tonn, and Hans A Kretzschmar, and Ludwig C Hinske, and Friedrich W Kreth
January 2009, Journal of neuro-oncology,
Simone Kreth, and Niklas Thon, and Sabina Eigenbrod, and Juergen Lutz, and Carola Ledderose, and Rupert Egensperger, and Joerg C Tonn, and Hans A Kretzschmar, and Ludwig C Hinske, and Friedrich W Kreth
January 2012, Neurology India,
Simone Kreth, and Niklas Thon, and Sabina Eigenbrod, and Juergen Lutz, and Carola Ledderose, and Rupert Egensperger, and Joerg C Tonn, and Hans A Kretzschmar, and Ludwig C Hinske, and Friedrich W Kreth
December 2011, Biochimica et biophysica acta,
Simone Kreth, and Niklas Thon, and Sabina Eigenbrod, and Juergen Lutz, and Carola Ledderose, and Rupert Egensperger, and Joerg C Tonn, and Hans A Kretzschmar, and Ludwig C Hinske, and Friedrich W Kreth
November 2010, The Journal of clinical endocrinology and metabolism,
Simone Kreth, and Niklas Thon, and Sabina Eigenbrod, and Juergen Lutz, and Carola Ledderose, and Rupert Egensperger, and Joerg C Tonn, and Hans A Kretzschmar, and Ludwig C Hinske, and Friedrich W Kreth
June 2010, Neuropathology and applied neurobiology,
Simone Kreth, and Niklas Thon, and Sabina Eigenbrod, and Juergen Lutz, and Carola Ledderose, and Rupert Egensperger, and Joerg C Tonn, and Hans A Kretzschmar, and Ludwig C Hinske, and Friedrich W Kreth
January 2014, Leukemia research,
Simone Kreth, and Niklas Thon, and Sabina Eigenbrod, and Juergen Lutz, and Carola Ledderose, and Rupert Egensperger, and Joerg C Tonn, and Hans A Kretzschmar, and Ludwig C Hinske, and Friedrich W Kreth
August 2014, Neuropathology : official journal of the Japanese Society of Neuropathology,
Copied contents to your clipboard!